WO2006133353A3 - Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics - Google Patents
Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics Download PDFInfo
- Publication number
- WO2006133353A3 WO2006133353A3 PCT/US2006/022268 US2006022268W WO2006133353A3 WO 2006133353 A3 WO2006133353 A3 WO 2006133353A3 US 2006022268 W US2006022268 W US 2006022268W WO 2006133353 A3 WO2006133353 A3 WO 2006133353A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- methods
- cell survival
- neural cell
- facilitating neural
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/68—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
Abstract
Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008515915A JP5461009B2 (en) | 2005-06-08 | 2006-06-08 | Method for promoting neuronal cell survival using non-peptide and peptide BDNF neurotrophin analogues |
EP06784665A EP1893192A4 (en) | 2005-06-08 | 2006-06-08 | Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68876705P | 2005-06-08 | 2005-06-08 | |
US60/688,767 | 2005-06-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006133353A2 WO2006133353A2 (en) | 2006-12-14 |
WO2006133353A3 true WO2006133353A3 (en) | 2009-04-30 |
Family
ID=37499118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/022268 WO2006133353A2 (en) | 2005-06-08 | 2006-06-08 | Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics |
Country Status (5)
Country | Link |
---|---|
US (2) | US8686045B2 (en) |
EP (3) | EP2581440B1 (en) |
JP (1) | JP5461009B2 (en) |
ES (1) | ES2569881T3 (en) |
WO (1) | WO2006133353A2 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GEP20094629B (en) | 2003-03-19 | 2009-03-10 | Biogen Idec Inc | Nogo receptor binding protein |
WO2006002437A2 (en) | 2004-06-24 | 2006-01-05 | Biogen Idec Ma Inc. | Treatment of conditions involving demyelination |
EP2586445A1 (en) * | 2005-04-15 | 2013-05-01 | University Of North Carolina At Chapel Hill | Methods of facilitating cell survival using neurotrophin mimetics |
US20110230479A1 (en) * | 2005-04-15 | 2011-09-22 | Longo Frank M | Neurotrophin mimetics and uses thereof |
JP5461009B2 (en) | 2005-06-08 | 2014-04-02 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | Method for promoting neuronal cell survival using non-peptide and peptide BDNF neurotrophin analogues |
EP2238986A3 (en) | 2005-07-08 | 2010-11-03 | Biogen Idec MA Inc. | Sp35 antibodies and uses thereof |
AU2007337809A1 (en) * | 2006-12-20 | 2008-07-03 | Rinat Neuroscience Corporation | TrkB agonists for treating autoimmune disorders |
AU2008311251B9 (en) * | 2007-10-11 | 2014-04-17 | Biogen Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and TrkB agonists |
US20110123553A1 (en) * | 2007-11-08 | 2011-05-26 | Biogen Idec Ma Inc. | Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination |
US20110217280A1 (en) * | 2007-12-19 | 2011-09-08 | Vollrath Benedikt | Methods for treating neuropsychiatric conditions |
WO2009086204A2 (en) * | 2007-12-21 | 2009-07-09 | Afraxis, Inc. | Methods for treating neuropsychiatric conditions |
US8058406B2 (en) | 2008-07-09 | 2011-11-15 | Biogen Idec Ma Inc. | Composition comprising antibodies to LINGO or fragments thereof |
AR076601A1 (en) | 2009-05-21 | 2011-06-22 | Chlorion Pharma Inc | PYRIMIDINS AS THERAPEUTIC AGENTS |
KR101138048B1 (en) | 2009-11-06 | 2012-04-23 | 성균관대학교산학협력단 | Novel peptides upregulating BDNF expression and pharmaceutical composition for protection and therapy against Alzheimer's disease and Parkinson's disease comprising the same |
US10273219B2 (en) | 2009-11-12 | 2019-04-30 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
CA3125909C (en) | 2009-11-12 | 2023-10-31 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
JP2013513588A (en) | 2009-12-11 | 2013-04-22 | ジーンコード エーエス | Method for facilitating survival of neural cells using mimic or RET signaling pathway activators of GDNF family ligand (GFL) |
WO2011150347A2 (en) * | 2010-05-28 | 2011-12-01 | Pharmatrophix | Non-peptide bdnf neurotrophin mimetics |
JP2015518829A (en) | 2012-05-14 | 2015-07-06 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | LINGO-2 antagonist for treatment of conditions involving motor neurons |
JP6120311B2 (en) * | 2013-02-12 | 2017-04-26 | 学校法人銀杏学園 | Polyphenol compounds |
CN110590592A (en) * | 2013-03-15 | 2019-12-20 | 特罗菲克斯制药股份有限公司 | Non-peptide BDNF neurotrophin mimetics |
BR112015022832A2 (en) * | 2013-03-15 | 2017-07-18 | Pharmatrophix Inc | non-peptide bdnf neurotrophin mimetics |
US9447132B2 (en) | 2013-04-12 | 2016-09-20 | Achillion Pharmaceuticals, Inc. | Highly active nucleoside derivative for the treatment of HCV |
CA2972259A1 (en) | 2014-12-26 | 2016-06-30 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
EP3242893A1 (en) | 2015-01-08 | 2017-11-15 | Biogen MA Inc. | Lingo-1 antagonists and uses for treatment of demyelinating disorders |
CN107614686A (en) | 2015-05-29 | 2018-01-19 | 小利兰·斯坦福大学托管委员会 | For the nucleoside agents for the detrimental activity for reducing the gene containing the trinucleotide repeat sequence extended |
US10066229B2 (en) | 2015-07-28 | 2018-09-04 | Otonomy, Inc. | Treatment using truncated Trk B and Trk C antagonists |
CA3010615C (en) | 2016-01-14 | 2024-02-20 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
BR112020010581A2 (en) | 2017-12-07 | 2020-11-10 | Emory University | pharmaceutical composition, pressurized container, and, methods to treat or prevent a viral infection and to treat or prevent human coronavirus, sars, coronavirus mers, eastern equine encephalitis virus, western equine encephalitis virus, Venezuelan equine encephalitis virus, chikungunya virus and infection by ross river infection, orthomyxoviridae virus or paramyxoviridae virus or rsv virus, or infection by influenza a virus and influenza b virus or filoviridae virus or ebola virus. |
AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
BR112022024071A2 (en) | 2020-05-27 | 2022-12-20 | Axial Therapeutics Inc | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USES |
EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
TW202334089A (en) | 2021-11-02 | 2023-09-01 | 美商夫雷爾醫療公司 | Pparg inverse agonists and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030211982A1 (en) * | 2000-01-18 | 2003-11-13 | Saragovi Horacio Uri | Beta turn peptidomimetic cyclic compounds |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2109262A5 (en) | 1970-10-08 | 1972-05-26 | Inst Francais Du Petrole | |
US3953416A (en) * | 1971-12-20 | 1976-04-27 | Karl Folkers | Synthetic decapeptide having the activity of the luteinizing hormone releasing hormone and method for manufacturing the same |
JPS5025442B2 (en) * | 1972-03-14 | 1975-08-23 | ||
DE2343037A1 (en) | 1973-08-25 | 1975-03-06 | Hoechst Ag | MEDICINAL PRODUCTS WITH ANTIDEPRESSIVE EFFECT |
HU185535B (en) * | 1982-05-25 | 1985-02-28 | Mta Koezponti Hivatala | Process for preparing new gonadoliberin derivatives |
US5321029A (en) | 1988-11-14 | 1994-06-14 | Beecham-Wuelfing Gmbh & Co.K.G. | Xanthines |
GB9402331D0 (en) | 1994-02-07 | 1994-03-30 | Univ Mcgill | Nerve growth factor structural analogs and their uses |
WO1996016980A1 (en) | 1994-11-29 | 1996-06-06 | Novartis Ag | Morpholinoethylamide derivatives |
US5958875A (en) | 1996-03-29 | 1999-09-28 | The Regents Of The University Of California | Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity |
US6448031B1 (en) * | 1996-06-13 | 2002-09-10 | Itoham Foods Inc. | Process for producing LH-RH derivatives |
ATE277609T1 (en) | 1998-07-30 | 2004-10-15 | Abbott Lab | GLUCOCORTICOID SELECTIVE ANTI-INFLAMMATORY AGENTS |
MXPA01009213A (en) | 1999-03-17 | 2002-10-11 | Univ North Carolina | Method of screening candidate compounds for susceptibility to biliary excretion. |
US6583148B1 (en) | 1999-04-08 | 2003-06-24 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic substituted pyrimidines |
WO2002060867A2 (en) | 2001-01-29 | 2002-08-08 | Insight Strategy And Marketing Ltd | Carbazole derivatives and their uses as heparanase inhibitors |
WO2004028466A2 (en) | 2002-09-25 | 2004-04-08 | Georiga Tech Research Corporation | Ketoamide inhibitors in chronic nerve disease |
EP2586445A1 (en) | 2005-04-15 | 2013-05-01 | University Of North Carolina At Chapel Hill | Methods of facilitating cell survival using neurotrophin mimetics |
JP5461009B2 (en) | 2005-06-08 | 2014-04-02 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | Method for promoting neuronal cell survival using non-peptide and peptide BDNF neurotrophin analogues |
-
2006
- 2006-06-08 JP JP2008515915A patent/JP5461009B2/en active Active
- 2006-06-08 US US11/449,381 patent/US8686045B2/en active Active
- 2006-06-08 EP EP12169982.1A patent/EP2581440B1/en active Active
- 2006-06-08 EP EP06784665A patent/EP1893192A4/en not_active Withdrawn
- 2006-06-08 ES ES12169982.1T patent/ES2569881T3/en active Active
- 2006-06-08 WO PCT/US2006/022268 patent/WO2006133353A2/en active Application Filing
- 2006-06-08 EP EP12169984.7A patent/EP2526942B1/en active Active
-
2014
- 2014-01-27 US US14/165,090 patent/US9604907B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030211982A1 (en) * | 2000-01-18 | 2003-11-13 | Saragovi Horacio Uri | Beta turn peptidomimetic cyclic compounds |
Non-Patent Citations (1)
Title |
---|
LONGO ET AL.: "Neurotrophin Small Molecule Mimetics: Candidate Therapeutic Agents for Neurological Disorders.", CURR. MED. CHEM., vol. 5, no. 1, 2005, pages 29 - 41, XP008125095 * |
Also Published As
Publication number | Publication date |
---|---|
EP2581440A2 (en) | 2013-04-17 |
EP2581440B1 (en) | 2016-03-16 |
EP1893192A4 (en) | 2010-03-31 |
EP2526942A3 (en) | 2013-07-17 |
US20140200277A1 (en) | 2014-07-17 |
JP5461009B2 (en) | 2014-04-02 |
EP2526942A2 (en) | 2012-11-28 |
WO2006133353A2 (en) | 2006-12-14 |
ES2569881T3 (en) | 2016-05-12 |
EP2526942B1 (en) | 2017-08-09 |
US20070060526A1 (en) | 2007-03-15 |
EP1893192A2 (en) | 2008-03-05 |
US8686045B2 (en) | 2014-04-01 |
JP2008545793A (en) | 2008-12-18 |
EP2581440A3 (en) | 2013-06-26 |
US9604907B2 (en) | 2017-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006133353A3 (en) | Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics | |
WO2006012642A3 (en) | Pyrrole derivatives as pharmaceutical agents | |
WO2007095586A3 (en) | Neuronal pain pathway modulators | |
WO2006020680A3 (en) | Heterocyclic compounds as pharmaceutical agents | |
WO2006034373A3 (en) | Variants and chemically-modified variants of phenylalanine ammonia-lyase | |
WO2006023359A3 (en) | Selective vpac2 receptor peptide agonists | |
WO2006052608A3 (en) | Treatment of obesity and related disorders | |
WO2006037016A3 (en) | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury | |
WO2008051797A3 (en) | Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases | |
WO2006020060A3 (en) | Iap binding compounds | |
WO2005115439A3 (en) | Cerberus/coco derivatives and uses thereof | |
HK1108442A1 (en) | Rapamcyin analogues and the uses thereof in the treatment of neurological, proliferative and inflammatory disorders | |
WO2007045927A3 (en) | Therapeutic agent | |
IL178427A0 (en) | 1,2-diarylimidazole-4-carboxamide compounds, processes for their preparation and use thereof in the treatment of obesity, psychiatric and neurological disorders | |
ZA200801825B (en) | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: Preparation and use to treat neuropsychiatric disorders | |
WO2005009387A3 (en) | Azepine derivatives as pharmaceutical agents | |
WO2003026479A3 (en) | Methods of suppressing microglial activation | |
ZA200802645B (en) | Novel azetidine compounds useful in the treatment of functional gastrointestinal disorders, IBS and functional dyspepsia | |
WO2008080045A3 (en) | Dr6 antibodies inhibiting the binding of dr6 to app, and uses thereof in treating neurological disorders | |
WO2007030761A3 (en) | Acyclic 1,4-diamines and uses thereof | |
EP2476681A3 (en) | Amino-aza-adamantane derivatives and methods of use | |
PL1972637T3 (en) | huTNFR1 selective antagonists | |
WO2003047514A3 (en) | Reducing myelin-mediated inhibition of axon regeneration | |
WO2008008224A3 (en) | Sour taste receptor compositions and methods | |
WO2006135694A3 (en) | Uii-modulating compounds and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2008515915 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006784665 Country of ref document: EP |